Login to Your Account

Other News To Note

Wednesday, June 20, 2012
• Bavarian Nordic A/S, of Kvistgaard, Denmark, received a $17.9 million five-year contract from the National Institute of Allergy and Infectious Diseases to support development of candidate vaccine technologies to combat the intentional release of pathogens considered a threat to public health.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription